Cardiothoracic
Conference Coverage
CTO PCI success rates rising, with blip during COVID-19, registry shows
Updated results from the PROGRESS-CTO registry of chronic total occlusion percutaneous coronary angioplasty cases reports improving outcomes over...
Conference Coverage
No-implant interatrial shunt remains patent at a year
A no-implant interatrial shunting procedure showed improved wedge pressure and quality of life for up to 3 months in heart failure recipients.
Feature
ISCHEMIA substudy data don’t add up, cardiac surgeons say
Discrepancies between the paper and supplemental data have been slow to come to light, but the substudy authors say it’s a simple formatting error...
From the Journals
Bronchoscopic lung reduction boosts survival in severe COPD
From the Journals
Porcine virus a suspect in man’s death after pig heart transplant
That PCMV escaped detection before the operation “could now factor into some people’s questions over whether the experiment should have taken...
Guidelines
First-ever best practices for percutaneous axillary access
A new position statement from the Society for Cardiovascular Angiography and Interventions suggests best practices for this increasingly...
FDA/CDC
FDA clears mavacamten (Camzyos) for obstructive hypertrophic cardiomyopathy
Mavacamten is a first-in-class allosteric and reversible inhibitor selective for cardiac myosin that targets the underlying pathophysiology of...
FDA/CDC
FDA warns of pump defect with Medtronic HVAD system
Patients with the ventricular assist device could develop pump thrombosis caused by a welding defect in the internal pump, the FDA said in a...
Conference Coverage
TAVI device shows less deterioration than surgery 5 years out
A transcatheter aortic valve – CoreValve Evolut – is associated for first time with less deterioration than surgical repair at 5 years.
Conference Coverage
Extraction of infected implanted cardiac devices rare, despite guidelines
Prompt extraction for implantable device infections is guideline recommended but not often performed.
Conference Coverage
VALOR-HCM: Novel drug may delay, avert invasive therapy in OHCM
Mavacamten looks promising as a medical alternative to highly invasive septal reduction therapy for patients with obstructive hypertrophic...